¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other postprocedural disorders of nervous system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • registration system
    ½Å°íÁ¦µµ, µî·ÏÁ¦µµ
  • remote afterloading system
    ¿ø°ÝÁ¶ÀÛÈÄÀåÁø¹ý
  • reproductive system
    »ý½Ä°èÅë
  • respiratory system
    È£Èí°èÅë
  • reticuloendothelial system
    ±×¹°³»ÇǰèÅë, ¼¼¸Á³»ÇǰèÅë
  • Rh blood group system
    ¾Ë¿¡ÃëÇ÷¾×Çü±º
  • self-system
    ÀÚ±âü°è
  • system
    °èÅë, ÀåÄ¡, Á¦µµ
  • scavenging system
    ¸¶Ãë°¡½ºÁ¦°Åü°è
  • skeletal system
    »À´ë°èÅë
  • social security system
    »çȸº¸ÀåÁ¦µµ
  • somatosensory system
    ¸ö°¨°¢°èÅë
  • sound conduction system
    ¼Ò¸®Àü´Þ°èÅë, ÀüÀ½°è
  • static system
    Á¤Áö°è
  • stereotactic system
    Á¤À§°íÁ¤±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • impulse conducting system
    ÈïºÐÆÄÀüµµ°è.
  • impulse conduction system
    ÈïºÐÆÄÀüµµ°è.
  • impulse conduction system
    ÈïºÐÆÄÀüµµ°è(ýéÝÇ÷îîîÓôͧ).
  • inference system
    ÃßÃø°è
  • infusion-aspiration system
    ÁÖÀÔÈíÀÔÀåÄ¡
  • pituitary adrenal system
    ÇϼöüºÎ½ÅÇÇÁú°è(¡­Üùãìù«òõͧ).
  • pituitary portal system
    ³úÇϼöü¹®¸Æ°è(¡­Ú¦ØæÍ§).
  • pneumatic tube system
    ±â¼Û°üÀåÄ¡(ѨáêηíûöÇ)
  • portal system
    ¹®¸Æ°è(Ú¦ØæÍ§).
  • pride system
    ÀÚ±àü°è£¨í»Ðèô÷ͧ£©
  • primary signal system
    ÀÏÂ÷½ÅÈ£°è(ìéó­ãáûÜ Í§).
  • primary signalling system
    ÀÏÂ÷Àû¡¡½Åȣü°è
  • primitive duct system
    ¿ø½Ã°ü°èÅë
  • projective system
    Åõ»çü°è
  • real time system
    ½Ç½Ã°£ ü°è
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • voice disorders, psychogenic
    ½ÉÀÎ(¼º) À½¼ºÀå¾Ö
  • x linked disorders
    X¿¬°ü(XÀÇÁ¸)Àå¾Ö, X¿¬°üÁúº´
  • achromatic system
    ¹«»ö°è.
  • acid-base buffer system
    »ê¿°±â¿ÏÃæ°è
  • adrenal medulla,tumor of chemoreceptor system
    È­Çмö¿ëü°è Á¾¾ç(ûùùÊáôé»ô÷ͧ ðþåË)
  • adrenal system
    ºÎ½Å°è(Üùãìͧ).
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • affectional system
    Á¤µ¿Ã¼°è
  • alimentary system(tract)
    ¼ÒÈ­±â°è(á¼ûùÐïͧ)
  • anaerobic culture system
    ¹«»ê¼Ò¹è¾çÀåÄ¡, ¹«»ê¼Ò¹è¾ç±â, ¹«»ê¼ÒÀåÄ¡
  • ancillary immune system
    º¸Á¶Àû ¸é¿ª°è
  • anemia expert system
    ºóÇ÷Àü¹®°¡½Ã½ºÅÛ
  • annular phased array system, APAS
    À§»óµ¿±âÀ±»ó¹è¿­½Ã½ºÅÛ
  • archicortical system
    ¿ø½ÃÇÇÁú°è(¡­Í§)
  • array system
    ¹è¿­ ÀåÄ¡ (¹è¿­ ü°è)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
OPL other party liability; outer plexiform layer; ovine placental lactogen
ORM orosomucoid; other regulated material; oxygen ratio monitor
OTPS other than personal services
qod every other day [Lat. quaque altera die]
qoh every other hour [Lat. quaque altera hora]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
PBD Peroxisome biogenesis disorders
PT-LPDs Post-transplantation lymphoproliferative disorders
PRIME-MD Primary Care Evaluation of Mental Disorders
SADS-L Schedule for Affective Disorders and Schizophrenia Lifetime Version
SRBD Sleep-Related Breathing Disorders
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oil immersion system
    À¯Ä§ ÀåÄ¡
  • open vessel system
    °³¹æ ¼øÈ¯°è
  • opiate sensitive system
    ¾ÆÆí¼º °¨¼º°è
  • opioid-mediated analgesia system
    ¾ÆÆí ¸Å°³ ÁøÅë°è
  • osseous system
    »À ±â°ü, °ñ°è
  • oxidation reduction system
    »êÈ­ ȯ¿ø°è
  • pain system
    µ¿Åë°è
  • pain transmission system
    µ¿Åë Àü´Þ°è
  • pain-modulating system
    µ¿Åë Á¶Àý°è
    ÁßÃß ½Å°æ°è´Â Åë°¢À» Àü´ÞÇÏ¿© ÅëÁõÀ» ´À³¢°Ô ÇÏ´Â ±â´É À̿ܿ¡µµ µ¿ÅëÀ» ÅëÁ¦ÇÏ´Â ÀÏ·ÃÀÇ ½Å°æ Á¶Á÷À» °®°í ÀÖÀ¸¸ç, ½Å°æ ¼¼Æ÷¿¡¼­ o
  • pallidal system
    ´ãⱸ°è
  • palm and sole system of identification
    ¼öÀå Á·Àú È®Àιý
  • peripheral pain sensory system
    ¸»Ãʼº Åë°¢°è
  • peripheral vascular system
    ¸»ÃÊÇ÷°ü°è
  • pindex system technique
    Çɵ¦½º¹ý
  • pituitary adrenal system
    Çϼöü ºÎ½Å ÇÇÁú°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
speech disorders Long-term disorders in speaking or in perception of speech.
(12 Dec 1998)
necrobiotic disorders A group of disorders characterised by swelling, basophilia, and distortion of collagen bundles in the dermis.
(12 Dec 1998)
neurotic disorders Disorders in which the symptoms are distressing to the individual and recognised by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.
(12 Dec 1998)
stress disorders, posttraumatic Anxiety disorders manifested by the development of characteristic symptoms following a psychologically traumatic event that is outside the normal range of usual human experience. Symptoms include re-experiencing the traumatic event and numbing of responsiveness to or reduced involvement with the external world.
(12 Dec 1998)
substance abuse disorders A class of mental disorders in which behavioural and biological changes are associated with regular use of alcohol, drugs, and related substances that affect the central nervous system and personal and social functioning.
(05 Mar 2000)
substance-induced organic mental disorders Mental disorders caused by use of drugs, e.g., cocaine.
(05 Mar 2000)
substance-related disorders These non-psychotic disorders include those related to the taking of a drug of abuse (including alcohol), to the side effects of a medication, and to toxin exposure.
(12 Dec 1998)
delirium, dementia, amnestic, cognitive disorders Cognitive disorders including delirium, dementia, and other cognitive disorders. These may be the result of substance use, trauma, or other causes.
(12 Dec 1998)
disorders, myeloproliferative Tumours of certain bone marrow cells including those that give rise to red cells, granulocytes, and platelets. As opposed to the lymphoproliferative disorders.
(12 Dec 1998)
dissociative disorders Sudden temporary alterations in the normally integrative functions of consciousness.
(12 Dec 1998)
immunodeficiency disorders <radiology> B-cell (antibody) deficiency: high-grade pathogens: pneumococcus, strep, H. Flu, chronic sinopulmonary disease, usual survival to adulthood, T-cell (cellular) deficiency: low-grade pathogens: fungi, viruses, Pneumocystic, growth retardation, diarrhoea, delayed anergy, short life-span, susceptible to graft vs. Host (GvH) disease, e.g.: DiGeorge syndrome, Nezelhof syndrome Note: increased risk of malignancy
(12 Dec 1998)
immunoproliferative disorders Disorders characterised by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins.
(12 Dec 1998)
impulse control disorders Disorders whose essential features are the failure to resist an impulse, drive, or temptation to perform an act that is harmful to the individual or to others. Individuals experience an increased sense of tension prior to the act and pleasure, gratification or release of tension at the time of committing the act.
(12 Dec 1998)
infant nutrition disorders Malnutrition, occurring in infants ages 1 month to 24 months, which is due to insufficient intake of food, dietary nutrients, or a pathophysiologic condition which prevents the absorption and utilization of food. Growth and development are markedly affected.
(12 Dec 1998)
iron metabolism disorders Disorders in the processing of iron in the body: its absorption, transport, storage, and utilization.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • sprinkler system
    ÀÚµ¿ »ì¼ö ¼ÒÈ­ ÀåÄ¡
  • stagger system
    (ÃâÅð±Ù ½Ã°£ µûÀ§ÀÇ)½ÃÂ÷Á¦
  • system
    Á¶Á÷;ü°è;°èÅë;Çм³;Á¦µµ;¹æ½Ä;¹æ¹ý;¼ø¼­;°è;¿ìÁÖ
  • talkingdown system
    ¹«Àü À¯µµ ¹æ½Ä
  • track system
    Çзº° ¹ÝÆí¼º
  • truck system
    (ÀÓ±ÝÀÇ) Çö¹° Áö±ÞÁ¦
  • twoparty system
    2´ë Á¤´çÁ¦
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á